Filing Details

Accession Number:
0001179110-13-011153
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-07-01 16:38:58
Reporting Period:
2013-07-01
Filing Date:
2013-07-01
Accepted Time:
2013-07-01 16:38:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434868 Esperion Therapeutics Inc. ESPR Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1242612 S Roger Newton C/O Esperion Therapeutics, Inc.
46701 Commerce Center Drive
Plymouth MI 48170
Executive Chairman, Cso Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-07-01 301,051 $0.00 587,337 No 4 C Direct
Common Stock Acquisiton 2013-07-01 42,346 $14.00 629,683 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2013-07-01 301,051 $0.00 301,051 $0.00
Series A Preferred Stock Warrant to Purchase Preferred Stock Disposition 2013-07-01 242,082 $0.00 242,082 $1.00
Common Stock Warrant to Purchase Common Stock Acquisiton 2013-07-01 34,651 $0.00 34,651 $6.99
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 2018-02-12 No 4 J Direct
34,651 2018-02-12 No 4 J Direct
Footnotes
  1. The Series A Preferred Stock was automatically converted into Common Stock on a 6.986-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date.
  2. The warrant is immediately exercisable.
  3. Upon the closing of the Issuer's initial public offering, this warrant to purchase shares of Series A Preferred Stock automatically converted on a 6.986-for-1 basis into a warrant to purchase shares of Common Stock, and the exercise price automatically adjusted accordingly. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrant and the change in exercise price.